Skip to content
Screener

CapEx at other companies

Natera, Inc. logo
Natera, Inc.NTRA
$63.43M+145%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
$5.2M+10.3%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
-$22.53M-400%
Personalis, Inc. logo
Personalis, Inc.PSNL
$3.19M+27.1%
NeoGenomics logo
NeoGenomicsNEO
$8.22M+30.0%
Quest Diagnostics logo
Quest DiagnosticsDGX
$138M+27.8%

Other financials

Income statement

See full
Revenue$102.3M+17.4%
Gross profit$68.2M+16.6%
Operating income-$57.5M-1,163%
Net income-$63.3M-870%
EPS (diluted)-$2.16-839%

Balance sheet

See full
Cash & equivalents$94.9M-5.7%
Total debt$96.7M+82.5%
Total equity$254.1M-1.3%
Total assets$506.3M+13.4%

Cash flow

See full
Operating cash flow-$32.4M-418%
Free cash flow-$38.9M-1,059%

Valuation

See full
Market cap$2.08B-31.7%
Enterprise value$2.08B-31.2%
P/S4.7×-3.7×

Profitability

See full
Gross margin69.6%+4.3pp
Operating margin-14.9%
Net margin-17.6%
FCF margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-30.4%
Debt / equity0.4×+0.2×
Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The source filing: GeneDx Holdings’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001818331-26-000041
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Purchases of marketable securities(20,177)(17,209)
Proceeds from sales of marketable securities875
Proceeds from maturities of marketable securities8,50013,930
Purchases of property and equipment and development of internal-use software(6,453)(6,129)
Net cash used in investing activities(17,255)(9,408)
Financing activities
Proceeds from long term debt, net of issuance costs96,99813,894
Proceeds from issuance of common stock from subscription agreements476

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is GeneDx Holdings's capex?
GeneDx Holdings (WGS) reported capex of $6.45M in Q1 2026.
How has GeneDx Holdings's capex changed year-over-year?
GeneDx Holdings's capex increased by 5.3% year-over-year, from $6.13M to $6.45M.
What is the long-term trend for GeneDx Holdings's capex?
Over 4 years (2021 to 2025), GeneDx Holdings's capex has grown at a 19.3% compound annual growth rate (CAGR), from $9.4M to $19.02M.
What does capex mean?
Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.

Ask your AI about GeneDx Holdings's capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude